Eurobio Scientific Société anonyme (EPA: ALERS)
France
· Delayed Price · Currency is EUR 25.80
0.00 (0.00%)
Nov 20, 2024, 5:35 PM CET
ALERS Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 144.73 | 130.65 | 152.9 | 185.32 | 189.19 | 59.48 | Upgrade
|
| Revenue | 144.73 | 130.65 | 152.9 | 185.32 | 189.19 | 59.48 | Upgrade
|
| Revenue Growth (YoY) | 13.11% | -14.55% | -17.49% | -2.04% | 218.10% | 16.46% | Upgrade
|
| Cost of Revenue | 77.9 | 73.16 | 81.66 | 85.91 | 80.68 | 41.13 | Upgrade
|
| Gross Profit | 66.83 | 57.49 | 71.24 | 99.41 | 108.51 | 18.35 | Upgrade
|
| Selling, General & Admin | 39.82 | 33.52 | 31 | 24.5 | 22.5 | 14.94 | Upgrade
|
| Research & Development | 5.71 | 5.91 | 3.47 | - | - | - | Upgrade
|
| Other Operating Expenses | - | - | - | - | - | -0 | Upgrade
|
| Operating Expenses | 53.93 | 47.35 | 40.37 | 29.29 | 27.3 | 17.78 | Upgrade
|
| Operating Income | 12.9 | 10.14 | 30.87 | 70.12 | 81.21 | 0.57 | Upgrade
|
| Interest Expense | -4.26 | -4.36 | -1.26 | -0.41 | -0.6 | -0.7 | Upgrade
|
| Interest & Investment Income | 1.25 | 1.12 | 0.04 | - | 0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.91 | 0.75 | 0.67 | 0.36 | -0.19 | 0.82 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.67 | 0.77 | 0.04 | -0.05 | 0.44 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | 11.47 | 8.42 | 30.35 | 70.01 | 80.86 | 0.65 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.23 | - | - | Upgrade
|
| Other Unusual Items | -1.5 | -1.45 | -0.67 | 1.08 | 0.03 | -0.49 | Upgrade
|
| Pretax Income | 9.97 | 6.98 | 29.68 | 71.31 | 80.89 | 0.16 | Upgrade
|
| Income Tax Expense | 3.32 | 2.14 | 4.75 | 10.77 | 7.41 | -2.99 | Upgrade
|
| Earnings From Continuing Operations | 6.64 | 4.84 | 24.94 | 60.54 | 73.48 | 3.15 | Upgrade
|
| Net Income | 6.64 | 4.84 | 24.94 | 60.54 | 73.48 | 3.15 | Upgrade
|
| Net Income to Common | 6.64 | 4.84 | 24.94 | 60.54 | 73.48 | 3.15 | Upgrade
|
| Net Income Growth | -15.98% | -80.61% | -58.81% | -17.61% | 2230.51% | - | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | 8.96% | -1.40% | 4.59% | -3.35% | 0.11% | 14.75% | Upgrade
|
| EPS (Basic) | 0.60 | 0.43 | 2.20 | 5.58 | 6.56 | 0.29 | Upgrade
|
| EPS (Diluted) | 0.60 | 0.43 | 2.20 | 5.57 | 6.53 | 0.28 | Upgrade
|
| EPS Growth | -22.45% | -80.44% | -60.53% | -14.70% | 2232.14% | - | Upgrade
|
| Free Cash Flow | 19.96 | 22.71 | 40.24 | 64.07 | 52.63 | 3.4 | Upgrade
|
| Free Cash Flow Per Share | 1.79 | 2.02 | 3.54 | 5.89 | 4.68 | 0.30 | Upgrade
|
| Gross Margin | 46.18% | 44.00% | 46.59% | 53.64% | 57.35% | 30.85% | Upgrade
|
| Operating Margin | 8.91% | 7.76% | 20.19% | 37.84% | 42.93% | 0.96% | Upgrade
|
| Profit Margin | 4.59% | 3.70% | 16.31% | 32.67% | 38.84% | 5.30% | Upgrade
|
| Free Cash Flow Margin | 13.79% | 17.39% | 26.32% | 34.57% | 27.82% | 5.71% | Upgrade
|
| EBITDA | 20.63 | 18.99 | 40.5 | 77.98 | 88.22 | 6.94 | Upgrade
|
| EBITDA Margin | 14.25% | 14.53% | 26.49% | 42.08% | 46.63% | 11.67% | Upgrade
|
| D&A For EBITDA | 7.73 | 8.85 | 9.63 | 7.87 | 7.01 | 6.37 | Upgrade
|
| EBIT | 12.9 | 10.14 | 30.87 | 70.12 | 81.21 | 0.57 | Upgrade
|
| EBIT Margin | 8.91% | 7.76% | 20.19% | 37.84% | 42.93% | 0.96% | Upgrade
|
| Effective Tax Rate | 33.34% | 30.70% | 15.99% | 15.10% | 9.16% | - | Upgrade
|
| Revenue as Reported | 144.73 | 130.65 | 152.9 | 185.32 | 189.19 | 59.48 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.